Form 4: MapLight CMO Sells Shares for Tax Obligations

MapLight Therapeutics' Chief Medical Officer, Erin Pennock Foff, disposed of 44,616 common shares to cover tax withholding obligations.

Summary

• Chief Medical Officer Erin Pennock Foff disposed of 44,616 shares of MapLight Therapeutics, Inc. common stock.
• The transaction occurred on January 27, 2026, at a price of $17.98 per share.
• This disposition was for tax withholding obligations in connection with the settlement of restricted stock unit awards.
• Following the transaction, Ms. Foff beneficially owns 390,475 shares of common stock.
• The securities retained by Ms. Foff remain subject to a 180-day lock-up agreement from the initial public offering's final prospectus date of October 26, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax purposes, which does not reflect a change in the executive's confidence or the company's fundamentals.

Future Outlook

No specific forward-looking statements or guidance are provided beyond the existing lock-up agreement for the reporting person's remaining shares, which expires 180 days after October 26, 2025.

Industry Context

StockSavvy.ai notes that tax-related dispositions of shares by executives are common and typically not indicative of a change in sentiment towards the company, especially following restricted stock unit settlements. This is a routine event in executive compensation.

Comparison to Industry Standards

• Tax withholding on restricted stock unit settlements is a standard practice across industries for executive compensation, ensuring compliance with tax obligations upon vesting.
• Lock-up agreements, such as the 180-day period mentioned, are also standard in initial public offerings to prevent market saturation and maintain price stability post-IPO.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale indicating a change in executive sentiment.

Next Steps

• The lock-up agreement for the reporting person's remaining shares will expire 180 days after October 26, 2025, at which point those shares may become eligible for sale, subject to company policy and market conditions.

Key Dates

Recommendation

This Form 4 filing details a non-discretionary sale of shares by the Chief Medical Officer to cover tax obligations arising from restricted stock unit settlements. Such transactions are routine and do not typically signal a change in the company's fundamentals or management's outlook. Therefore, a 'hold' recommendation is appropriate as this specific filing provides no new information to alter an existing investment thesis.

Keywords

MapLight Therapeutics, MPLT, Form 4, insider transaction, stock sale, tax withholding, Chief Medical Officer, Erin Pennock Foff, restricted stock units